EGFR and lung adenocarcinoma: Targeted NGS analysis helped predict the prognosis and recurrence of patients with resected EGFR-mutation lung adenocarcinoma and benefitted in the identification of patients with a high risk of recurrence for selection for adjuvant EGFR-TKIs treatment.